Nothing Special   »   [go: up one dir, main page]

MX2014004709A - Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio. - Google Patents

Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio.

Info

Publication number
MX2014004709A
MX2014004709A MX2014004709A MX2014004709A MX2014004709A MX 2014004709 A MX2014004709 A MX 2014004709A MX 2014004709 A MX2014004709 A MX 2014004709A MX 2014004709 A MX2014004709 A MX 2014004709A MX 2014004709 A MX2014004709 A MX 2014004709A
Authority
MX
Mexico
Prior art keywords
magnesium
composition
promotion
retention
absorption
Prior art date
Application number
MX2014004709A
Other languages
English (en)
Other versions
MX354727B (es
Inventor
Clara Garcia-Rodenas
Mattias Hoppler
Elizabeth Offord Cavin
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004709(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2014004709A publication Critical patent/MX2014004709A/es
Publication of MX354727B publication Critical patent/MX354727B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Pediatric Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dairy Products (AREA)

Abstract

La invención divulga una composición que comprende una mezcla de oligosacáridos, dicha mezcla contiene al menos un oligosacárido N-acetilado, al menos un oligosacárido sialilado y al menos un oligosacárido neutro, para uso en la promoción de absorción de magnesio y/o retención de magnesio. La composición preferentemente además comprende al menos un ácido graso poliinsaturado de cadena larga y/o al menos un probiótico. Esta composición está particularmente adaptada para su uso en lactantes, especialmente lactantes prematuros.
MX2014004709A 2011-10-18 2012-10-15 Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio. MX354727B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185610 2011-10-18
PCT/EP2012/070404 WO2013057072A1 (en) 2011-10-18 2012-10-15 Composition for use in the promotion of magnesium absorption and/or magnesium retention

Publications (2)

Publication Number Publication Date
MX2014004709A true MX2014004709A (es) 2015-02-05
MX354727B MX354727B (es) 2018-03-16

Family

ID=47022680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004709A MX354727B (es) 2011-10-18 2012-10-15 Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio.

Country Status (15)

Country Link
US (1) US9781947B2 (es)
EP (1) EP2768313B2 (es)
CN (1) CN103906435B (es)
AU (1) AU2012324993B2 (es)
BR (1) BR112014007829A2 (es)
CL (1) CL2014000792A1 (es)
ES (1) ES2546262T5 (es)
MX (1) MX354727B (es)
PH (1) PH12014500344A1 (es)
PL (1) PL2768313T3 (es)
PT (1) PT2768313E (es)
RU (1) RU2604502C2 (es)
TW (1) TW201316993A (es)
WO (1) WO2013057072A1 (es)
ZA (1) ZA201403592B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3248605A1 (en) 2009-07-06 2017-11-29 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
ES2992190T3 (es) * 2016-08-04 2024-12-10 Nestle Sa Composiciones nutritivas y fórmulas infantiles que comprenden una mezcla de oligosacáridos y, opcionalmente, Bifidobacterium lactis para prevenir, tratar o reducir la gravedad de la diarrea asociada a no rotavirus
WO2020033708A1 (en) * 2018-08-08 2020-02-13 Mars, Incorporated Pet food products comprising oligosaccharides and methods of use
CN114145458A (zh) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 棕榈酸甘油酯在制备改善或促进人体镁吸收的组合物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180674A (en) 1990-04-16 1993-01-19 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
JPH08283162A (ja) 1995-04-10 1996-10-29 Snow Brand Milk Prod Co Ltd ミネラル吸収促進剤
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
US5906982A (en) * 1997-03-31 1999-05-25 Abbott Laboratories Nutritional formulations containing Lacto-N-neoTetraose
GB0028238D0 (en) 2000-11-20 2001-01-03 Cerestar Holding Bv Indigestible oligosaccharides and magnesium absorption in humans
US7435431B2 (en) 2004-07-28 2008-10-14 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
CA2641842A1 (en) * 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
EP1993576B1 (en) * 2006-03-07 2015-10-21 Nestec S.A. Synbiotic mixture
WO2008027572A1 (en) * 2006-08-30 2008-03-06 Prolacta Bioscience Methods of obtaining sterile milk and compositions thereof
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
WO2008153377A1 (en) * 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
MX2010009978A (es) * 2008-03-14 2010-11-30 Nestec Sa Mezcla simbiotica.
WO2010068086A1 (en) * 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
CN106890329A (zh) * 2009-07-15 2017-06-27 N·V·努特里奇亚 用于刺激免疫系统的不可消化低聚糖的混合物
EP2509429A1 (en) * 2009-12-08 2012-10-17 Nestec S.A. Infant formula with probiotics and milk fat globule membrane components
EP2455387A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
CN103596440A (zh) 2011-06-08 2014-02-19 雀巢产品技术援助有限公司 含有外源性乳脂肪球膜组分的营养组合物

Also Published As

Publication number Publication date
PL2768313T3 (pl) 2016-02-29
RU2014119845A (ru) 2015-11-27
WO2013057072A1 (en) 2013-04-25
PH12014500344A1 (en) 2014-04-14
CL2014000792A1 (es) 2014-08-22
AU2012324993A1 (en) 2014-02-27
CN103906435B (zh) 2016-11-23
AU2012324993A2 (en) 2014-06-12
EP2768313A1 (en) 2014-08-27
PT2768313E (pt) 2015-10-14
EP2768313B2 (en) 2019-01-02
CN103906435A (zh) 2014-07-02
BR112014007829A2 (pt) 2017-04-18
RU2604502C2 (ru) 2016-12-10
ES2546262T5 (es) 2019-04-12
MX354727B (es) 2018-03-16
US9781947B2 (en) 2017-10-10
TW201316993A (zh) 2013-05-01
US20140255543A1 (en) 2014-09-11
AU2012324993B2 (en) 2015-11-26
ZA201403592B (en) 2015-12-23
ES2546262T3 (es) 2015-09-22
EP2768313B1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
MY170185A (en) Composition for use in brain growth and/or cognitive and/or psychomotor development
MX2014004719A (es) Composicion para su uso en la promocion de la angiogenesis intestinal y de la absorcion de nutrientes y de tolerancia a la alimentacion enteral y/o en la prevencion y/o en el tratamiento de la inflamacion intestinal y/o en la recuperacion posterior a un daño o cirugia intestinal.
PH12014500558A1 (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
PH12014500453A1 (en) Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
IN2015DN03862A (es)
PH12017500387A1 (en) Composition comprising fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition
IN2014DN07483A (es)
PH12014500344A1 (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention
NZ702930A (en) Racecadotril liquid compositions
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
IN2014DN08385A (es)
BR112013028820A2 (pt) alimento medicinal para declínio cognitivo
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
PH12013502563A1 (en) Dha and epa in the reduction of oxidative stress
NZ626540A (en) Glutamine enriched nutritional composition for preterm infants
PH12014501569A1 (en) Glutamine enriched nutritional composition for preterm infants
GB201003894D0 (en) Inhibitors of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome
TH146971A (th) องค์ประกอบสำหรับการใช้ในการส่งเสริมการดูดซึมแมกนีเซียม และ/หรือ การกักเก็บแมกนีเซียม
BR112014015193A2 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico
PH12012500873A1 (en) Multilayer pharmaceutical composition that can be dispersed in water and which contains a combination of antimalarial agents
MY147148A (en) Nutrition with lipids and non-digestible saccharides
UA60256U (ru) Способ патогенетической профилактики и лечения внутрижелудочковых кровоизлияний (вжк) у новорожденных
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием

Legal Events

Date Code Title Description
FG Grant or registration